CN118019734A - 环戊基吡唑cdk2抑制剂 - Google Patents

环戊基吡唑cdk2抑制剂 Download PDF

Info

Publication number
CN118019734A
CN118019734A CN202280065852.1A CN202280065852A CN118019734A CN 118019734 A CN118019734 A CN 118019734A CN 202280065852 A CN202280065852 A CN 202280065852A CN 118019734 A CN118019734 A CN 118019734A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
ring
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280065852.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·M·格兰德纳
K·M·约翰逊
S·马格努森
J·M·穆雷
B·T·帕尔
V·A·韦尔马
王涌
曾明烁
M·A·阿什利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN118019734A publication Critical patent/CN118019734A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280065852.1A 2021-10-05 2022-10-04 环戊基吡唑cdk2抑制剂 Pending CN118019734A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252394P 2021-10-05 2021-10-05
US63/252,394 2021-10-05
PCT/US2022/077501 WO2023060057A1 (en) 2021-10-05 2022-10-04 Cyclopentylpyrazole cdk2 inhibitors

Publications (1)

Publication Number Publication Date
CN118019734A true CN118019734A (zh) 2024-05-10

Family

ID=84245758

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280065852.1A Pending CN118019734A (zh) 2021-10-05 2022-10-04 环戊基吡唑cdk2抑制剂

Country Status (10)

Country Link
US (1) US20240425478A1 (https=)
EP (1) EP4412995A1 (https=)
JP (1) JP2024538694A (https=)
KR (1) KR20240077491A (https=)
CN (1) CN118019734A (https=)
AR (1) AR127247A1 (https=)
AU (1) AU2022360968A1 (https=)
CA (1) CA3229067A1 (https=)
TW (1) TW202330501A (https=)
WO (1) WO2023060057A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120247874A (zh) * 2022-04-28 2025-07-04 正大天晴药业集团股份有限公司 一种吡唑取代环戊酯衍生物及其用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
CN120239698A (zh) * 2022-11-17 2025-07-01 山东绿叶制药有限公司 Cdk2抑制剂及其制备方法和应用
WO2025136671A1 (en) * 2023-12-20 2025-06-26 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113330000B (zh) * 2019-01-31 2024-12-24 辉瑞公司 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物
CN110536068B (zh) 2019-09-29 2021-09-28 Oppo广东移动通信有限公司 对焦方法和装置、电子设备、计算机可读存储介质
TW202246255A (zh) * 2021-02-12 2022-12-01 美商傳達治療有限公司 Ｃｄｋ抑制劑及其使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120247874A (zh) * 2022-04-28 2025-07-04 正大天晴药业集团股份有限公司 一种吡唑取代环戊酯衍生物及其用途
CN120247874B (zh) * 2022-04-28 2026-02-24 正大天晴药业集团股份有限公司 一种吡唑取代环戊酯衍生物及其用途

Also Published As

Publication number Publication date
AR127247A1 (es) 2024-01-03
US20240425478A1 (en) 2024-12-26
WO2023060057A1 (en) 2023-04-13
EP4412995A1 (en) 2024-08-14
AU2022360968A1 (en) 2024-02-29
CA3229067A1 (en) 2023-04-13
KR20240077491A (ko) 2024-05-31
JP2024538694A (ja) 2024-10-23
TW202330501A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
CN118019734A (zh) 环戊基吡唑cdk2抑制剂
KR101530117B1 (ko) 야누스 키나제 억제제 화합물 및 방법
JP6404717B2 (ja) アミドスピロ環状アミド及びスルホンアミド誘導体
CA3030070A1 (en) Heterocyclic compound used as fgfr inhibitor
KR102589213B1 (ko) 피리미딘 사이클로헥세닐 글루코코르티코이드 수용체 조절제
CN109790166A (zh) 咪唑并吡啶化合物用于治疗癌症
CN105073114B (zh) 用于呼吸疾病的药物
JP2020526557A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
EP3665175B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP6545262B2 (ja) Ｒｉｐｋ２阻害剤およびそれを用いた癌の治療方法
CN114728945A (zh) 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN114746414A (zh) 氮杂-喹啉化合物及其用途
CA3145864A1 (en) Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
CN112996783B (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
TWI835476B (zh) 哌嗪吲唑糖皮質素受體拮抗劑
TW201536783A (zh) 用於治療增生性失調之新穎化合物及其醫藥組合物
CN108299436B (zh) 黄嘌呤类化合物及其药物组合物和应用
CN107428762A (zh) 酞嗪酮衍生物、其制备方法及用途
HK40110722A (zh) 环戊基吡唑cdk2抑制剂
WO2025034912A9 (en) Compounds for fgfr inhibition
WO2025067258A1 (zh) 哒嗪酮类化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
HK40077297A (en) Aza-quinoline compounds and uses thereof
CN114907406A (zh) 嘧啶衍生物、其制备方法及其在医药上的应用
HK1243407B (en) Ripk2 inhibitors and method of treating cancer with same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110722

Country of ref document: HK